{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:27:41Z","timestamp":1790108861587,"version":"4.0.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-24262-7","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T14:15:50Z","timestamp":1763475350000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Identifying high-risk drugs and demographic patterns in drug-induced liver injury from FAERS and CVARD analyses"],"prefix":"10.1038","volume":"15","author":[{"given":"Yun","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Dong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Nan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Bing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-He","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Hang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Shuo","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Zhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Hong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-Ping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Zhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"24262_CR1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00018-025-05744-3","volume":"82","author":"J Skat-R\u00f8rdam","year":"2025","unstructured":"Skat-R\u00f8rdam, J., Lykkesfeldt, J., Gluud, L. L. & Tveden-Nyborg, P. Mechanisms of drug induced liver injury. Cell Mol. Life Sci. 82, 213. https:\/\/doi.org\/10.1007\/s00018-025-05744-3 (2025).","journal-title":"Cell Mol. Life Sci."},{"key":"24262_CR2","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1146\/annurev-pathmechdis-051122-094016","volume":"19","author":"H Jaeschke","year":"2024","unstructured":"Jaeschke, H. & Ramachandran, A. Acetaminophen hepatotoxicity: Paradigm for understanding mechanisms of drug-induced liver injury. Annu. Rev. Pathol. 19, 453\u2013478. https:\/\/doi.org\/10.1146\/annurev-pathmechdis-051122-094016 (2024).","journal-title":"Annu. Rev. Pathol."},{"key":"24262_CR3","doi-asserted-by":"publisher","first-page":"e70002","DOI":"10.1111\/liv.70002","volume":"45","author":"P Chodup","year":"2025","unstructured":"Chodup, P., Samodelov, S. L., Visentin, M. & Kullak-Ublick, G. A. Drug-induced liver injury associated with emerging cancer therapies. Liver Int. 45, e70002. https:\/\/doi.org\/10.1111\/liv.70002 (2025).","journal-title":"Liver Int."},{"key":"24262_CR4","doi-asserted-by":"publisher","first-page":"116056","DOI":"10.1016\/j.bcp.2024.116056","volume":"228","author":"A Ramachandran","year":"2024","unstructured":"Ramachandran, A., Akakpo, J. Y., Curry, S. C., Rumack, B. H. & Jaeschke, H. Clinically relevant therapeutic approaches against acetaminophen hepatotoxicity and acute liver failure. Biochem. Pharmacol. 228, 116056. https:\/\/doi.org\/10.1016\/j.bcp.2024.116056 (2024).","journal-title":"Biochem. Pharmacol."},{"key":"24262_CR5","doi-asserted-by":"publisher","unstructured":"N C, E B. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 2010 https:\/\/doi.org\/10.1053\/j.gastro.2010.04.001.","DOI":"10.1053\/j.gastro.2010.04.001"},{"issue":"1419\u201325","key":"24262_CR6","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1053\/j.gastro.2013.02.006","volume":"144","author":"ES Bj\u00f6rnsson","year":"2013","unstructured":"Bj\u00f6rnsson, E. S., Bergmann, O. M., Bj\u00f6rnsson, H. K., Kvaran, R. B. & Olafsson, S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 144(1419\u201325), 1425. https:\/\/doi.org\/10.1053\/j.gastro.2013.02.006 (2013).","journal-title":"Gastroenterology"},{"key":"24262_CR7","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1053\/j.gastro.2019.02.002","volume":"156","author":"T Shen","year":"2019","unstructured":"Shen, T. et al. Incidence and etiology of drug-induced liver injury in mainland China. Gastroenterology 156, 2230-2241.e11. https:\/\/doi.org\/10.1053\/j.gastro.2019.02.002 (2019).","journal-title":"Gastroenterology"},{"key":"24262_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2021.10.035","author":"B Hk","year":"2022","unstructured":"Hk, B. & Es, B. Drug-induced liver injury: Pathogenesis, epidemiology, clinical features, and practical management. Eur. J. Intern. Med. https:\/\/doi.org\/10.1016\/j.ejim.2021.10.035 (2022).","journal-title":"Eur. J. Intern. Med."},{"key":"24262_CR9","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/ueg2.12113","volume":"9","author":"ES Bj\u00f6rnsson","year":"2021","unstructured":"Bj\u00f6rnsson, E. S. Clinical management of patients with drug-induced liver injury (DILI). United Eur. Gastroenterol. J. 9, 781\u2013786. https:\/\/doi.org\/10.1002\/ueg2.12113 (2021).","journal-title":"United Eur. Gastroenterol. J."},{"key":"24262_CR10","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.jhep.2021.10.011","volume":"76","author":"ES Bj\u00f6rnsson","year":"2022","unstructured":"Bj\u00f6rnsson, E. S. & Andrade, R. J. Long-term sequelae of drug-induced liver injury. J. Hepatol. 76, 435\u2013445. https:\/\/doi.org\/10.1016\/j.jhep.2021.10.011 (2022).","journal-title":"J. Hepatol."},{"key":"24262_CR11","doi-asserted-by":"publisher","unstructured":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, Clinical Practice Guideline Panel: Chair:, Panel members, EASL Governing Board representative: EASL Clinical Practice Guidelines: Drug-induced liver injury. J. Hepatol. 70 1222\u201361. https:\/\/doi.org\/10.1016\/j.jhep.2019.02.014. 2019.","DOI":"10.1016\/j.jhep.2019.02.014"},{"key":"24262_CR12","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00204-020-02963-4","volume":"95","author":"N Todorovi\u0107 Vukoti\u0107","year":"2021","unstructured":"Todorovi\u0107 Vukoti\u0107, N., \u0110or\u0111evi\u0107, J., Peji\u0107, S., \u0110or\u0111evi\u0107, N. & Pajovi\u0107, S. B. Antidepressants- and antipsychotics-induced hepatotoxicity. Arch. Toxicol. 95, 767\u2013789. https:\/\/doi.org\/10.1007\/s00204-020-02963-4 (2021).","journal-title":"Arch. Toxicol."},{"key":"24262_CR13","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1097\/HEP.0000000000000458","volume":"78","author":"RT Stravitz","year":"2023","unstructured":"Stravitz, R. T. et al. Future directions in acute liver failure. Hepatology 78, 1266\u20131289. https:\/\/doi.org\/10.1097\/HEP.0000000000000458 (2023).","journal-title":"Hepatology"},{"key":"24262_CR14","doi-asserted-by":"publisher","first-page":"825","DOI":"10.7150\/ijms.16185","volume":"13","author":"M Takada","year":"2016","unstructured":"Takada, M., Fujimoto, M. & Hosomi, K. Association between Benzodiazepine use and dementia: Data mining of different medical databases. Int. J. Med. Sci. 13, 825\u2013834. https:\/\/doi.org\/10.7150\/ijms.16185 (2016).","journal-title":"Int. J. Med. Sci."},{"key":"24262_CR15","doi-asserted-by":"publisher","first-page":"e0144337","DOI":"10.1371\/journal.pone.0144337","volume":"10","author":"TB Ali","year":"2015","unstructured":"Ali, T. B., Schleret, T. R., Reilly, B. M., Chen, W. Y. & Abagyan, R. Adverse effects of cholinesterase inhibitors in dementia, according to the pharmacovigilance databases of the United-States and Canada. PLoS ONE 10, e0144337. https:\/\/doi.org\/10.1371\/journal.pone.0144337 (2015).","journal-title":"PLoS ONE"},{"key":"24262_CR16","doi-asserted-by":"publisher","first-page":"4424","DOI":"10.1016\/j.apsb.2022.04.019","volume":"12","author":"J Wang","year":"2022","unstructured":"Wang, J. et al. Landscape of DILI-related adverse drug reaction in China mainland. Acta Pharm. Sin B 12, 4424\u20134431. https:\/\/doi.org\/10.1016\/j.apsb.2022.04.019 (2022).","journal-title":"Acta Pharm. Sin B"},{"key":"24262_CR17","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda, T., Tamon, A., Kadoyama, K. & Okuno, Y. Data mining of the public version of the FDA adverse event reporting system. Int J. Med. Sci. 10, 796\u2013803. https:\/\/doi.org\/10.7150\/ijms.6048 (2013).","journal-title":"Int J. Med. Sci."},{"key":"24262_CR18","unstructured":"Vision for MedDRA|MedDRA n.d. https:\/\/www.meddra.org\/about-meddra\/vision (accessed October 13, 2024)."},{"key":"24262_CR19","unstructured":"Canada H. Data extracts from the Canada vigilance adverse reaction online database 2009. https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/medeffect-canada\/adverse-reaction-database\/canada-vigilance-online-database-data-extract.html (accessed Oct. 13, 2024)."},{"key":"24262_CR20","unstructured":"FAERS Quarterly Data Extract Files n.d. https:\/\/fis.fda.gov\/extensions\/FPD-QDE-FAERS\/FPD-QDE-FAERS.html (accessed Oct. 13, 2024)."},{"key":"24262_CR21","doi-asserted-by":"publisher","first-page":"1480269","DOI":"10.3389\/fphar.2024.1480269","volume":"15","author":"X-D Chen","year":"2024","unstructured":"Chen, X.-D., Xiao, K.-H. & Zhou, C.-B. Drug-induced retinal vein occlusion: A disproportionality analysis from the FDA adverse event reporting system (2004\u20132023). Front. Pharmacol. 15, 1480269. https:\/\/doi.org\/10.3389\/fphar.2024.1480269 (2024).","journal-title":"Front. Pharmacol."},{"key":"24262_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.14454","author":"S-N Wu","year":"2024","unstructured":"Wu, S.-N. et al. Drug-associated glaucoma: A real-world study based on the food and drug administration adverse event reporting system database. Clin. Exp. Ophthalmol. https:\/\/doi.org\/10.1111\/ceo.14454 (2024).","journal-title":"Clin. Exp. Ophthalmol."},{"key":"24262_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1167\/tvst.13.9.17","volume":"13","author":"S-N Wu","year":"2024","unstructured":"Wu, S.-N. et al. Drug-related keratitis: A real-world fda adverse event reporting system database study. Transl. Vis. Sci. Technol. 13, 17. https:\/\/doi.org\/10.1167\/tvst.13.9.17 (2024).","journal-title":"Transl. Vis. Sci. Technol."},{"key":"24262_CR24","doi-asserted-by":"publisher","first-page":"100104","DOI":"10.1016\/j.apjo.2024.100104","volume":"13","author":"S-N Wu","year":"2024","unstructured":"Wu, S.-N. et al. Real-world large sample assessment of drug-related dry eye risk: Based on the FDA adverse event reporting system database. Asia Pac. J. Ophthalmol. (Phila) 13, 100104. https:\/\/doi.org\/10.1016\/j.apjo.2024.100104 (2024).","journal-title":"Asia Pac. J. Ophthalmol. (Phila)"},{"key":"24262_CR25","doi-asserted-by":"publisher","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","volume":"46","author":"DS Wishart","year":"2018","unstructured":"Wishart, D. S. et al. DrugBank 50: A major update to the DrugBank database for 2018. Nucleic Acids Res. 46, D1074\u2013D1082. https:\/\/doi.org\/10.1093\/nar\/gkx1037 (2018).","journal-title":"Nucleic Acids Res."},{"key":"24262_CR26","doi-asserted-by":"publisher","first-page":"1110575","DOI":"10.3389\/fphar.2023.1110575","volume":"14","author":"H Zhao","year":"2023","unstructured":"Zhao, H. et al. Sodium-glucose co-transporter-2 inhibitor (SGLT2i) treatment and risk of osteomyelitis: A pharmacovigilance study of the FAERS database. Front. Pharmacol. 14, 1110575. https:\/\/doi.org\/10.3389\/fphar.2023.1110575 (2023).","journal-title":"Front. Pharmacol."},{"key":"24262_CR27","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/S2468-1253(20)30006-6","volume":"5","author":"MI Lucena","year":"2020","unstructured":"Lucena, M. I., Sanabria, J., Garc\u00eda-Cortes, M., Stephens, C. & Andrade, R. J. Drug-induced liver injury in older people. Lancet Gastroenterol. Hepatol. 5, 862\u2013874. https:\/\/doi.org\/10.1016\/S2468-1253(20)30006-6 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"24262_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0105-0","author":"RJ Andrade","year":"2019","unstructured":"Andrade, R. J. et al. Drug-induced liver injury. Nat. Rev. Dis. Primers https:\/\/doi.org\/10.1038\/s41572-019-0105-0 (2019).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"24262_CR29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.dld.2022.06.025","volume":"55","author":"A Floreani","year":"2023","unstructured":"Floreani, A., Bizzaro, D., Shalaby, S., Taliani, G. & Burra, P. Special interest group gender in hepatology of the Italian association for the study of the liver (AISF). Sex disparity and drug-induced liver injury. Dig. Liver Dis. 55, 21\u201328. https:\/\/doi.org\/10.1016\/j.dld.2022.06.025 (2023).","journal-title":"Dig. Liver Dis."},{"key":"24262_CR30","doi-asserted-by":"publisher","first-page":"101355","DOI":"10.1016\/j.jcmgh.2024.05.003","volume":"18","author":"G Li","year":"2024","unstructured":"Li, G. et al. Interplay between drug-induced liver injury and gut microbiota: A comprehensive overview. Cell Mol. Gastroenterol. Hepatol. 18, 101355. https:\/\/doi.org\/10.1016\/j.jcmgh.2024.05.003 (2024).","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"24262_CR31","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ijpharm.2015.08.067","volume":"494","author":"T Caon","year":"2015","unstructured":"Caon, T., Campos, C. E. M., Sim\u00f5es, C. M. O. & Silva, M. A. S. Novel perspectives in the tuberculosis treatment: Administration of isoniazid through the skin. Int. J. Pharm. 494, 463\u2013470. https:\/\/doi.org\/10.1016\/j.ijpharm.2015.08.067 (2015).","journal-title":"Int. J. Pharm."},{"key":"24262_CR32","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.actbio.2022.01.054","volume":"142","author":"N Marasini","year":"2022","unstructured":"Marasini, N. et al. Development of a hyperbranched polymer-based methotrexate nanomedicine for rheumatoid arthritis. Acta Biomater. 142, 298\u2013307. https:\/\/doi.org\/10.1016\/j.actbio.2022.01.054 (2022).","journal-title":"Acta Biomater."},{"key":"24262_CR33","doi-asserted-by":"publisher","first-page":"835359","DOI":"10.3389\/fphar.2022.835359","volume":"13","author":"J Li","year":"2022","unstructured":"Li, J., Sun, R., Xu, H. & Wang, G. Integrative metabolomics, proteomics and transcriptomics analysis reveals liver toxicity of mesoporous silica nanoparticles. Front. Pharmacol. 13, 835359. https:\/\/doi.org\/10.3389\/fphar.2022.835359 (2022).","journal-title":"Front. Pharmacol."},{"key":"24262_CR34","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.cgh.2013.12.016","volume":"12","author":"R Vuppalanchi","year":"2014","unstructured":"Vuppalanchi, R. et al. Relationship between characteristics of medications and drug-induced liver disease phenotype and outcome. Clin. Gastroenterol. Hepatol. 12, 1550\u20131555. https:\/\/doi.org\/10.1016\/j.cgh.2013.12.016 (2014).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"24262_CR35","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.jhep.2016.08.006","volume":"65","author":"J Fern\u00e1ndez","year":"2016","unstructured":"Fern\u00e1ndez, J., Bert, F. & Nicolas-Chanoine, M.-H. The challenges of multi-drug-resistance in hepatology. J. Hepatol. 65, 1043\u20131054. https:\/\/doi.org\/10.1016\/j.jhep.2016.08.006 (2016).","journal-title":"J. Hepatol."},{"key":"24262_CR36","doi-asserted-by":"publisher","first-page":"104267","DOI":"10.1016\/j.phrs.2019.104267","volume":"145","author":"C Gervasoni","year":"2019","unstructured":"Gervasoni, C., Cattaneo, D., Filice, C. & Galli, M. \u201cGruppo Italiano Studio-NASH in malattie infettive.\u201d Drug-induced liver steatosis in patients with HIV infection. Pharmacol. Res. 145, 104267. https:\/\/doi.org\/10.1016\/j.phrs.2019.104267 (2019).","journal-title":"Pharmacol. Res."},{"key":"24262_CR37","doi-asserted-by":"publisher","first-page":"110916","DOI":"10.1016\/j.fct.2019.110916","volume":"135","author":"B Fromenty","year":"2020","unstructured":"Fromenty, B. Alteration of mitochondrial DNA homeostasis in drug-induced liver injury. Food Chem. Toxicol. 135, 110916. https:\/\/doi.org\/10.1016\/j.fct.2019.110916 (2020).","journal-title":"Food Chem. Toxicol."},{"key":"24262_CR38","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/apt.18160","volume":"60","author":"C Conlon","year":"2024","unstructured":"Conlon, C. et al. Clinical characteristics and HLA associations of azithromycin-induced liver injury. Aliment Pharmacol. Ther. 60, 787\u2013795. https:\/\/doi.org\/10.1111\/apt.18160 (2024).","journal-title":"Aliment Pharmacol. Ther."},{"key":"24262_CR39","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.apsb.2016.07.014","volume":"6","author":"P Wang","year":"2016","unstructured":"Wang, P., Pradhan, K., Zhong, X.-B. & Ma, X. Isoniazid metabolism and hepatotoxicity. Acta Pharm. Sin B 6, 384\u2013392. https:\/\/doi.org\/10.1016\/j.apsb.2016.07.014 (2016).","journal-title":"Acta Pharm. Sin B"},{"key":"24262_CR40","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","volume":"174","author":"JJ Saukkonen","year":"2006","unstructured":"Saukkonen, J. J. et al. An official ATS statement: Hepatotoxicity of antituberculosis therapy. Am. J. Respir. Crit. Care Med. 174, 935\u2013952. https:\/\/doi.org\/10.1164\/rccm.200510-1666ST (2006).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"24262_CR41","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1440-1746.2007.05207.x","volume":"23","author":"A Tostmann","year":"2008","unstructured":"Tostmann, A. et al. Antituberculosis drug-induced hepatotoxicity: Concise up-to-date review. J. Gastroenterol. Hepatol. 23, 192\u2013202. https:\/\/doi.org\/10.1111\/j.1440-1746.2007.05207.x (2008).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"24262_CR42","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1055\/s-0039-1679919","volume":"39","author":"A Ramachandran","year":"2019","unstructured":"Ramachandran, A. & Jaeschke, H. Acetaminophen hepatotoxicity. Semin. Liver Dis. 39, 221\u2013234. https:\/\/doi.org\/10.1055\/s-0039-1679919 (2019).","journal-title":"Semin. Liver Dis."},{"key":"24262_CR43","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1007\/s10620-016-4121-6","volume":"61","author":"AS deLemos","year":"2016","unstructured":"deLemos, A. S. et al. Amoxicillin-clavulanate-induced liver injury. Dig. Dis. Sci. 61, 2406\u20132416. https:\/\/doi.org\/10.1007\/s10620-016-4121-6 (2016).","journal-title":"Dig. Dis. Sci."},{"key":"24262_CR44","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1053\/j.gastro.2015.03.006","volume":"148","author":"N Chalasani","year":"2015","unstructured":"Chalasani, N. et al. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study. Gastroenterology 148, 1340-1352.e7. https:\/\/doi.org\/10.1053\/j.gastro.2015.03.006 (2015).","journal-title":"Gastroenterology"},{"key":"24262_CR45","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/cpt.2930","volume":"114","author":"S Gu","year":"2023","unstructured":"Gu, S. et al. Drug-induced liver injury with commonly used antibiotics in the all of us research program. Clin. Pharmacol. Ther. 114, 404\u2013412. https:\/\/doi.org\/10.1002\/cpt.2930 (2023).","journal-title":"Clin. Pharmacol. Ther."},{"key":"24262_CR46","doi-asserted-by":"publisher","first-page":"101741","DOI":"10.4254\/wjh.v17.i2.101741","volume":"17","author":"Y Zhao","year":"2025","unstructured":"Zhao, Y. et al. Clinical features and prognosis of drug-induced liver injury in patients with non-alcoholic fatty liver. World J. Hepatol. 17, 101741. https:\/\/doi.org\/10.4254\/wjh.v17.i2.101741 (2025).","journal-title":"World J. Hepatol."},{"key":"24262_CR47","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13613-023-01184-z","volume":"13","author":"T Tikiso","year":"2023","unstructured":"Tikiso, T. et al. Acute-on-chronic liver failure alters linezolid pharmacokinetics in critically ill patients with continuous hemodialysis: An observational study. Ann Intensive Care 13, 83. https:\/\/doi.org\/10.1186\/s13613-023-01184-z (2023).","journal-title":"Ann Intensive Care"},{"key":"24262_CR48","first-page":"213","volume":"79","author":"BT Moy","year":"2015","unstructured":"Moy, B. T., Dojki, F. K., Scholes, J. V. & Hoffman, M. G. Azithromycin-induced cholestatic hepatitis. Conn. Med. 79, 213\u2013215 (2015).","journal-title":"Conn. Med."},{"key":"24262_CR49","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1097\/MJT.0b013e3182a44055","volume":"22","author":"M Gulen","year":"2015","unstructured":"Gulen, M., Ay, M. O., Avci, A., Acikalin, A. & Icme, F. Levofloxacin-induced hepatotoxicity and death. Am. J. Ther. 22, e93-96. https:\/\/doi.org\/10.1097\/MJT.0b013e3182a44055 (2015).","journal-title":"Am. J. Ther."},{"key":"24262_CR50","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/liv.15821","volume":"44","author":"A Pocurull","year":"2024","unstructured":"Pocurull, A. et al. Anticancer drugs are the first cause of drug-induced liver injury in a reference hospital. Liver Int. 44, 286\u2013292. https:\/\/doi.org\/10.1111\/liv.15821 (2024).","journal-title":"Liver Int."},{"key":"24262_CR51","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1016\/j.apsb.2021.10.003","volume":"11","author":"L Shojaie","year":"2021","unstructured":"Shojaie, L., Ali, M., Iorga, A. & Dara, L. Mechanisms of immune checkpoint inhibitor-mediated liver injury. Acta Pharm. Sin B 11, 3727\u20133739. https:\/\/doi.org\/10.1016\/j.apsb.2021.10.003 (2021).","journal-title":"Acta Pharm. Sin B"},{"key":"24262_CR52","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1002\/ptr.6951","volume":"35","author":"J Chen","year":"2021","unstructured":"Chen, J., Li, Z., Hua, M. & Sun, Y. Protection by ginseng saponins against cyclophosphamide-induced liver injuries in rats by induction of cytochrome P450 expression and mediation of the l-arginine\/nitric oxide pathway based on metabolomics. Phytother. Res. 35, 3130\u20133144. https:\/\/doi.org\/10.1002\/ptr.6951 (2021).","journal-title":"Phytother. Res."},{"key":"24262_CR53","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1001\/jamaoncol.2023.1891","volume":"9","author":"L Sun","year":"2023","unstructured":"Sun, L. et al. association between duration of immunotherapy and overall survival in advanced non-small cell lung cancer. JAMA Oncol. 9, 1075\u20131082. https:\/\/doi.org\/10.1001\/jamaoncol.2023.1891 (2023).","journal-title":"JAMA Oncol."},{"key":"24262_CR54","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jhep.2011.07.023","volume":"56","author":"E Bj\u00f6rnsson","year":"2012","unstructured":"Bj\u00f6rnsson, E., Jacobsen, E. I. & Kalaitzakis, E. Hepatotoxicity associated with statins: Reports of idiosyncratic liver injury post-marketing. J. Hepatol. 56, 374\u2013380. https:\/\/doi.org\/10.1016\/j.jhep.2011.07.023 (2012).","journal-title":"J. Hepatol."},{"key":"24262_CR55","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1124\/pr.115.012203","volume":"68","author":"PJ Barter","year":"2016","unstructured":"Barter, P. J. & Rye, K.-A. New era of lipid-lowering drugs. Pharmacol. Rev. 68, 458\u2013475. https:\/\/doi.org\/10.1124\/pr.115.012203 (2016).","journal-title":"Pharmacol. Rev."},{"key":"24262_CR56","doi-asserted-by":"publisher","first-page":"116824","DOI":"10.1016\/j.lfs.2019.116824","volume":"235","author":"RE Elshaer","year":"2019","unstructured":"Elshaer, R. E. et al. Leflunomide-induced liver injury in mice: Involvement of TLR4 mediated activation of PI3K\/mTOR\/NF\u03baB pathway. Life Sci. 235, 116824. https:\/\/doi.org\/10.1016\/j.lfs.2019.116824 (2019).","journal-title":"Life Sci."},{"key":"24262_CR57","doi-asserted-by":"publisher","first-page":"106723","DOI":"10.1016\/j.intimp.2020.106723","volume":"86","author":"W Jiang","year":"2020","unstructured":"Jiang, W. et al. Roles of diclofenac and its metabolites in immune activation associated with acute hepatotoxicity in TgCYP3A4\/hPXR-humanized mice. Int. Immunopharmacol. 86, 106723. https:\/\/doi.org\/10.1016\/j.intimp.2020.106723 (2020).","journal-title":"Int. Immunopharmacol."},{"key":"24262_CR58","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/apt.15645","volume":"51","author":"ME Zoubek","year":"2020","unstructured":"Zoubek, M. E., Lucena, M. I., Andrade, R. J. & Stephens, C. Systematic review: Ibuprofen-induced liver injury. Aliment. Pharmacol. Ther. 51, 603\u2013611. https:\/\/doi.org\/10.1111\/apt.15645 (2020).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"24262_CR59","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1111\/liv.13662","volume":"38","author":"H Devarbhavi","year":"2018","unstructured":"Devarbhavi, H. et al. Drug-induced acute liver failure in children and adults: Results of a single-centre study of 128 patients. Liver Int. 38, 1322\u20131329. https:\/\/doi.org\/10.1111\/liv.13662 (2018).","journal-title":"Liver Int."},{"key":"24262_CR60","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jhep.2022.09.010","volume":"78","author":"N Chalasani","year":"2023","unstructured":"Chalasani, N. et al. Clinical features, outcomes, and HLA risk factors associated with nitrofurantoin-induced liver injury. J. Hepatol. 78, 293\u2013300. https:\/\/doi.org\/10.1016\/j.jhep.2022.09.010 (2023).","journal-title":"J. Hepatol."},{"key":"24262_CR61","doi-asserted-by":"publisher","first-page":"e0278725","DOI":"10.1371\/journal.pone.0278725","volume":"17","author":"Y Yang","year":"2022","unstructured":"Yang, Y. et al. A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for venetoclax. PLoS ONE 17, e0278725. https:\/\/doi.org\/10.1371\/journal.pone.0278725 (2022).","journal-title":"PLoS ONE"},{"key":"24262_CR62","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.jbspin.2006.09.002","volume":"73","author":"J-L Montastruc","year":"2006","unstructured":"Montastruc, J.-L. et al. Pharmacovigilance for evaluating adverse drug reactions: Value, organization, and methods. Joint Bone Spine 73, 629\u2013632. https:\/\/doi.org\/10.1016\/j.jbspin.2006.09.002 (2006).","journal-title":"Joint Bone Spine"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24262-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24262-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24262-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T02:04:01Z","timestamp":1763863441000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24262-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["24262"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-24262-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"13 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study utilized data from publicly available databases, FAERS and CVARD, which do not contain personally identifiable information and do not require ethical approval. Consistent with prior research involving these databases, no ethical review or approval from an Ethics Committee was required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"This study is a real-world pharmacovigilance investigation based on publicly accessible databases. As such, it does not involve a formal clinical trial, and therefore, no clinical trial registration number is applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"40579"}}